Overview

* Aura Biosciences ( AURA ) reports Q3 net loss of $26.1 mln, up from $21.0 mln last year

* R&D expenses rise to $22.2 mln due to ongoing clinical trials

Outlook

* Aura expects Phase 3 CoMpass trial enrollment completion in 2026

* Topline data for CoMpass trial expected in Q4 2027

* Phase 1b/2 trial data for NMIBC expected mid-2026

Result Drivers

* ENROLLMENT CHALLENGES - CoMpass trial enrollment faced delays due to requirement for active tumor growth and operational challenges, now improved

* R&D EXPENSES - Increased due to ongoing clinical trials and personnel growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$26.13

Income mln

Q3 $27.91

Operatin mln

g

Expenses

Q3 -$27.91

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Aura Biosciences Inc ( AURA ) is $21.00, about 73.5% above its November 12 closing price of $5.57

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)